The Semaglutide (Wegovy) Clinical Trial: Or How headline numbers mess with both Doctors and Patients minds
The recent SELECT study broadcast that using Wegovy size (2.4mg/weekly) dosages of Semaglutide for three years would reduce the risk of cardiovascular men events among some pretty seriously ill people by 20%. Unfortunately, when you dig deeper, what you discover is that what the study really showed is that if you treated 1,000 of these … Read more